Progress of chimeric antigen receptor T-cell for treatment of malignant lymphoma
10.3760/cma.j.issn.1009-9921.2018.01.002
- VernacularTitle:嵌合抗原受体T细胞治疗恶性淋巴瘤研究进展
- Author:
Zheng SONG
1
;
Xianhuo WANG
;
Lanfang LI
;
Lili YANG
;
Xiubao REN
;
Huilai ZHANG
Author Information
1. 300060,国家肿瘤临床医学研究中心 天津市肿瘤防治重点实验室 天津市恶性肿瘤临床医院研究中心 天津医科大学肿瘤医院淋巴瘤科
- Keywords:
Lymphoma;
Chimeric antigen receptor T-cell;
Clinical protocols
- From:
Journal of Leukemia & Lymphoma
2018;27(1):4-7
- CountryChina
- Language:Chinese
-
Abstract:
Chimeric antigen receptor T-cell (CAR-T) is one of the effective methods for treatment of lymphoma. The way to improve the efficacy and control the reverse reactions still needs to be explored further. Several clinical trials have indicated CAR-T could have favorable effects on the B-cell lymphoma patients with controllable reverse reactions. However, antigen loss is a major factor for the acquired resistance to CD19 CAR-T therapy. Other clinical researches, including CD22 for treatment of B-cell lymphoma and CD30 for Hodgkin lymphoma, have increased the efficacy of CAR-T. Moreover, lots of trials have suggested that the patients who received cyclophosphamide or bendamustine plus fludarabine lymphodepletion can get a high effective rate.
